David Lewis
Stock Analyst at Morgan Stanley
(2.77)
# 1,915
Out of 4,944 analysts
271
Total ratings
67.18%
Success rate
9.44%
Average return
Main Sectors:
Stocks Rated by David Lewis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | Maintains: Equal-Weight | $127 → $137 | $129.40 | +5.87% | 25 | Jul 15, 2025 | |
| PODD Insulet | Maintains: Equal-Weight | $273 → $300 | $308.68 | -2.81% | 22 | Nov 4, 2022 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $272 → $275 | $195.96 | +40.33% | 23 | Oct 11, 2022 | |
| DXCM DexCom | Maintains: Equal-Weight | $91 → $91 | $79.96 | +13.81% | 21 | Jun 15, 2022 | |
| OM Outset Medical | Maintains: Overweight | $750 → $720 | $13.21 | +5,350.42% | 6 | May 5, 2022 | |
| BAX Baxter International | Maintains: Overweight | $105 → $100 | $24.11 | +314.77% | 14 | Apr 29, 2022 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $22 → $15 | $132.04 | -88.64% | 7 | Feb 25, 2022 | |
| LUNG Pulmonx | Maintains: Equal-Weight | $37 → $30 | $1.54 | +1,848.05% | 6 | Feb 25, 2022 | |
| HOLX Hologic | Maintains: Equal-Weight | $76 → $75 | $68.98 | +8.73% | 11 | Feb 3, 2022 | |
| NVST Envista Holdings | Maintains: Equal-Weight | $42 → $45 | $21.56 | +108.72% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $68 → $60 | $53.88 | +11.36% | 12 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $82 | $62.79 | +30.59% | 5 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $478 → $431 | $122.92 | +250.63% | 10 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $154 | $92.91 | +65.75% | 17 | Aug 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $41 → $40 | $15.70 | +154.78% | 8 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $108 → $135 | $77.68 | +73.79% | 8 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $265 → $280 | $378.95 | -26.11% | 9 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $260 → $285 | $482.35 | -40.91% | 13 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $7.53 | +152.32% | 2 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $288 → $94 | $166.86 | -43.67% | 8 | Apr 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $79 | $86.48 | -8.65% | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $170 → $180 | $103.22 | +74.38% | 14 | Feb 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $187 | $174.42 | +7.21% | 11 | Jan 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $36 → $45 | $10.75 | +318.60% | 5 | Dec 15, 2020 |
Abbott Laboratories
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $127 → $137
Current: $129.40
Upside: +5.87%
Insulet
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $273 → $300
Current: $308.68
Upside: -2.81%
Becton, Dickinson and Company
Oct 11, 2022
Maintains: Overweight
Price Target: $272 → $275
Current: $195.96
Upside: +40.33%
DexCom
Jun 15, 2022
Maintains: Equal-Weight
Price Target: $91 → $91
Current: $79.96
Upside: +13.81%
Outset Medical
May 5, 2022
Maintains: Overweight
Price Target: $750 → $720
Current: $13.21
Upside: +5,350.42%
Baxter International
Apr 29, 2022
Maintains: Overweight
Price Target: $105 → $100
Current: $24.11
Upside: +314.77%
TransMedics Group
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $22 → $15
Current: $132.04
Upside: -88.64%
Pulmonx
Feb 25, 2022
Maintains: Equal-Weight
Price Target: $37 → $30
Current: $1.54
Upside: +1,848.05%
Hologic
Feb 3, 2022
Maintains: Equal-Weight
Price Target: $76 → $75
Current: $68.98
Upside: +8.73%
Envista Holdings
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $42 → $45
Current: $21.56
Upside: +108.72%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $68 → $60
Current: $53.88
Upside: +11.36%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $80 → $82
Current: $62.79
Upside: +30.59%
Oct 29, 2021
Maintains: Overweight
Price Target: $478 → $431
Current: $122.92
Upside: +250.63%
Aug 25, 2021
Maintains: Overweight
Price Target: $140 → $154
Current: $92.91
Upside: +65.75%
Aug 3, 2021
Maintains: Overweight
Price Target: $41 → $40
Current: $15.70
Upside: +154.78%
Jul 30, 2021
Maintains: Overweight
Price Target: $108 → $135
Current: $77.68
Upside: +73.79%
Apr 28, 2021
Maintains: Overweight
Price Target: $265 → $280
Current: $378.95
Upside: -26.11%
Apr 21, 2021
Maintains: Equal-Weight
Price Target: $260 → $285
Current: $482.35
Upside: -40.91%
Apr 19, 2021
Maintains: Overweight
Price Target: $18 → $19
Current: $7.53
Upside: +152.32%
Apr 14, 2021
Downgrades: Equal-Weight
Price Target: $288 → $94
Current: $166.86
Upside: -43.67%
Feb 25, 2021
Maintains: Overweight
Price Target: $75 → $79
Current: $86.48
Upside: -8.65%
Feb 8, 2021
Maintains: Overweight
Price Target: $170 → $180
Current: $103.22
Upside: +74.38%
Jan 27, 2021
Maintains: Overweight
Price Target: $178 → $187
Current: $174.42
Upside: +7.21%
Dec 15, 2020
Maintains: Underweight
Price Target: $36 → $45
Current: $10.75
Upside: +318.60%